Journal of Yeungnam Medical Science

Case reports

Hematology
Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: two case reports: Jin Ho Baek; J Yeungnam Med Sci. 2022;39(1):62-66. Published online April 19, 2021; DOI: https://doi.org/10.12701/yujm.2021.00934

9,153 View
111 Download
5 Web of Science
6 Crossref

Immune checkpoint inhibitor (ICI)-associated adrenal insufficiency is rare but may become a serious adverse event in patients treated with ICIs. The present case report documents two cases of adrenal insufficiency developed during chemotherapy plus tislelizumab (百泽安, Baize’an; BeiGene Ltd.) therapy in patients with advanced gastric cancer. Adrenal insufficiency developed after 6 and 13 cycles of treatment and was well controlled with hydrocortisone. The patients also developed hypothyroidism, which was managed with levothyroxine. Two patients showed a partial response, and one patient out of two achieved a near-complete response, sustaining over 11 months. Increased awareness of ICI-related adrenal insufficiency is crucial for early detection and prompt management of patients treated with ICIs.

Citations

Citations to this article as recorded by

A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment
Xiaomei Zhou, Yu Shu, Xi Chen, Bo Luo
Immunotherapy.2025; 17(7): 485. CrossRef
Analysis of adverse drug reactions in 507 cases of Tislelizumab: A real-world retrospective study based on data from Guangxi, China
Shaohuan Lu, Dajian Chen, Yang Li, Qianxi Chen, Guangyi Meng, Keiko Hosohata
PLOS One.2025; 20(8): e0329464. CrossRef
Immune checkpoint inhibitor-related adrenal hypofunction and Psoriasisby induced by tislelizumab: A case report and review of literature
Yisi Deng, Manling Huang, Runpei Deng, Jun Wang
Medicine.2024; 103(12): e37562. CrossRef
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
Frontiers in Oncology.2023;[Epub] CrossRef
Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
Qihao Zhou, Zhiquan Qin, Peiyuan Yan, Qunjiang Wang, Jing Qu, Yun Chen
Frontiers in Immunology.2023;[Epub] CrossRef
Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review
Shihao Li, Yi Zhu, Zhijian Xu, Jianjun Liu, Hongwei Liu
Frontiers in Oncology.2022;[Epub] CrossRef

Hematology
Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report: Dong Won Baek, Yee Soo Chae; Yeungnam Univ J Med. 2021;38(4):366-370. Published online March 23, 2021; DOI: https://doi.org/10.12701/yujm.2021.00899

9,529 View
138 Download
7 Crossref

Abstract PDF

Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.

Citations

Citations to this article as recorded by

Immunotherapy-associated autoimmune hemolytic anemia induced by anti-PD-1 therapy in esophageal cancer: A case report and literature review
Zijian Qiu, Mixue Sun, Chunyan Dai, Xiaoping Zhu
Medicine.2025; 104(15): e42174. CrossRef
Severe immunotherapy-related autoimmune hemolytic anemia induced by toripalimab in a patient with deficient mismatch repair colorectal cancer: a case report and literature review
Xu Ma, Jin-Sheng Ye, Zhi Liu, Quan-Li Geng
Frontiers in Medicine.2025;[Epub] CrossRef
Case Report: Life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma
Hang-Yu Gu, Jing-Wen Zhao, Yin-Shuang Wang, Zhuo-Nan Meng, Xiu-Ming Zhu, Fu-Wei Wang, Ai-Hong Zheng, Guo-Qing Wu
Frontiers in Immunology.2023;[Epub] CrossRef
Immunotherapy-associated Autoimmune Hemolytic Anemia
Steven R. Hwang, Antoine N. Saliba, Alexandra P. Wolanskyj-Spinner
Hematology/Oncology Clinics of North America.2022; 36(2): 365. CrossRef
Therapeutic plasma exchange in the management of immune checkpoint inhibitor‐associated immune‐related adverse effects: A review
Oluwatoyosi A. Onwuemene, Chizoba I. Nnoruka, Christopher J. Patriquin, Laura S. Connelly‐Smith
Transfusion.2022; 62(11): 2370. CrossRef
Diagnosis and management of cold agglutinin disease associated with low-grade B-cell lymphoma in a patient receiving pembrolizumab for lung cancer
Nabin Raj Karki, Peyton McElhone, Natasha Savage, Nagla Abdel Karim
BMJ Case Reports.2021; 14(8): e243751. CrossRef
Red Blood Cell Autoantibodies in Patients Treated with Immune Checkpoint Inhibitors
Eungjun Yoon, Tae Yeul Kim, Sun Kyoung Mun, Duck Cho
The Korean Journal of Blood Transfusion.2021; 32(3): 201. CrossRef

First
Prev
Page of 1
Next
Last

Search